References
Lamberts S.W.J., Krenning E.P., Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 1990, 12: 450.
Kwekkeboom D.J., de Herder W.W., Krenning E.P. Receptor imaging and treatment of pituitary tumors. J. Endocrinol. Invest. 1999, 22: 80.
Lamberts S.W.J., Uitterlinden P., Schuijff P.C., Klijn J.G. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustement and the definition of a biochemical “cure”. Clin. Endocrinol. (Oxf.) 1988, 29: 411.
Colao A., Ferone D., Lastoria S., Marzullo P., Cerbone G., Di Sarno A., Longobardi S., Merola B., Salvatore M., Lombardi G. Prediction of efficacy of octreotide therapy in patients with acromegaly. J. Clin. Endocrinol. Metab. 1996, 81: 2356.
van Royen E.A., Verhoeff N.P.L.G., Meylaerts S.A.G., Miedema A.R. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands. J. Nucl. Med. 1996, 37: 1449.
Plöckinger U., Bäder M., Hopfenmüller H., Saeger W., Quabbe H-J. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume and hormone-response to octreotide therapy and do not correlate with tumor histology. Eur. J. Endocrinol. 1997, 136: 369.
Colao A., Lastoria S., Ferone D., Varrella P., Marzullo P., Pivonello R., Cerbone G., Acampa W., Salvatore M., Lombardi G. Pituitary uptake of 111In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas. J. Endocrinol. Invest. 1999, 22: 176.
Bevan J.S., Webster J., Burke C.W., Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 1992, 13: 220.
de Herder W.W., Reijs A.E.M., Kwekkeboom D.J. In vivo imaging of pituitary tumors using a radiolabeled dopamine D2 receptor radioligand. Clin. Endocrinol. (Oxf.) 1996, 45: 755.
Scillitani A., Dicembrino F., Di Fazio P., Vettori P.P., D’Angelo V., Scarabino T., Liuzzi A. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxibenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. J. Clin. Endocrinol. Metab. 1995, 80: 2523.
Verhoeff N.P., Bemelman FJ., Wiersinga W.M., van Royen E.A. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with TSH/PRL-producing pituitary macroadenoma. Eur. J. Nucl. Med. 1993, 20: 555.
Ferone D., Lastoria S., Colao A., Varrella P., Cerbone G., Acampa W., Merola B., Salvatore M., Lombardi G. Correlation of scintigraphic results using 123I-Methoxibenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J. Clin. Endocrinol. Metab. 1998, 83: 248.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Colao, A., Lastoria, S., Lombardi, G. et al. Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest 22, 736–737 (1999). https://doi.org/10.1007/BF03343636
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343636